The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure

Doris Irene Stenver, L Jeppesen, B Nielsen, Jørn Dalsgaard Nielsen, C Haedersdal, J Mehlsen, K Winther

10 Citationer (Scopus)

Abstract

The influence of erythropoietin therapy on platelet function and fibrinolysis was evaluated in 12 anemic hemodialysis patients. Six months of therapy with human erythropoietin (50 to 80 IU/kg initially) raised the hemoglobin level to 10.8 g/dl but did not increase platelet activity in vivo as measured by beta-thromboglobulin or platelet factor 4. There was no change in the platelet aggregation thresholds in vitro for ADP, adrenaline, thrombin or collagen during treatment. Platelet number and volume were also unaffected. Fibrinolytic activity intensified as erythropoietin treatment proceeded, with a fall of euglobulin clot lysis time and rise in the activity of t-PA. PAI-1 levels also showed a downward trend, without reaching significance. Thus erythropoietin treatment in modest doses does not seem to adversely influence the hemostatic system in patients on hemodialysis.
OriginalsprogEngelsk
TidsskriftInternational Journal of Artificial Organs
Vol/bind17
Udgave nummer3
Sider (fra-til)141-5
Antal sider5
ISSN0391-3988
StatusUdgivet - 1 mar. 1994

Fingeraftryk

Dyk ned i forskningsemnerne om 'The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure'. Sammen danner de et unikt fingeraftryk.

Citationsformater